Actualités médicales et recherche

A Colorado qualitative interview study of 24 enrollment assisters reports perceived improvements in chronic disease care and fewer emergency visits, but demand outstripped limited slots and low insurance literacy created navigation and billing barriers.

In a phase 3 RCT of 142 adults, complete remission at 104 weeks was 37% with obinutuzumab vs 6% with tacrolimus, with similar rates of grade 3 or higher adverse events and infections.

Retrospective analysis of 374 SIPCA assessments across 173 MSF-supported facilities found IPC programme presence strongly associated with above-median scores and repeated audits improved low-baseline sites, while SSI surveillance remained a key gap at 40.6%.

In a prespecified exploratory analysis of a phase 3 randomized placebo-controlled trial of 903 patients, finerenone improved eGFR slope by 0.73 mL/min/1.73 m2 per year, cut albuminuria 42%, and lowered kidney failure or 40% eGFR decline with hazard ratio 0.74.